LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair

Despite advances in therapies treating non-Hodgkin’s lymphoma (NHL), 20~40% of patients experience relapsed or refractory disease. While solid tumors with homologous recombination deficiencies have been successfully targeted with synthetic lethal agents such as poly-ADP ribose polymerase (PARP) inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jianli, Sturtevant, Drew, Love, Cassie, Kulkarni, Aditya, Biyani, Neha, Kathad, Umesh, Thacker, Elizabeth, Dave, Sandeep, Bhatia, Kishor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259262/
https://www.ncbi.nlm.nih.gov/pubmed/37306526
http://dx.doi.org/10.18632/oncotarget.28454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259262/
https://www.ncbi.nlm.nih.gov/pubmed/37306526
http://dx.doi.org/10.18632/oncotarget.28454

Ejemplares similares